Background {#Sec1}
==========

Medical treatment of colorectal cancer (CRC) has significantly improved over the past 10 years, mostly because of the introduction of combination chemotherapy protocols, and, more recently, new biological agents \[[@CR1]\]. The median survival time of CRC patients has recently increased to over 2 years by using combinatorial therapy with molecular targeted agents such as bevacizumab, cetuximab, and panitumumab \[[@CR2]\].

However, in stage IV CRC with unresectable metastases, whether or not resection of the primary tumor should be indicated remains controversial. Although it has been previously demonstrated that primary tumor resection or palliative surgery against symptomatic primary tumors is valuable, opinions vary on the need for resection of asymptomatic primary tumors \[[@CR3],[@CR4]\]. The need for prophylactic resection of asymptomatic primary tumors to prevent emerging symptoms is debatable, and it is difficult to predict the contribution of such procedures to quality of life improvements, especially when the estimated survival time is limited \[[@CR5]\]. Moreover, it should be considered that patients with advanced CRC might have a higher risk of surgical morbidity and mortality \[[@CR6]-[@CR9]\].

Recent advances in systemic chemotherapy may result in initially unresectable metastases becoming resectable, and consequently, resection of the primary tumor can be reassessed as part of a multidisciplinary therapeutic process, instead of palliative care alone \[[@CR9]-[@CR13]\]. Conversely, others have reported that, during up-front systemic chemotherapy, 57.1% to 97.1% patients did not require the additional surgery for morbidity including obstruction, perforation, bleedings, and so forth, \[[@CR14]-[@CR17]\] and that the mean interval between diagnosis and start of chemotherapy was 23.1 days \[[@CR17]\]. As well as to avoid the unnecessary resection of primary tumor sometimes associated with surgical morbidity and mortality, up-front systemic chemotherapy was thought to be useful for earlier administration of chemotherapy for metastases that become life-threatening in the future and subsequently may contribute to prolong the survival outcomes.

Since the current literature does not offer confirmative evidence on the issue, we herein aimed to determine whether primary tumor resection followed by chemotherapy or up-front systemic chemotherapy provides a better prognosis in stage IV CRC with unresectable metastases.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We retrospectively investigated 103 patients with stage IV CRC, who did not have symptomatic primary tumor requiring emergency surgery and thus contraindicating up-front systemic chemotherapy, treated at the Department of Gastroenterological and Transplant Surgery, Hiroshima University Hospital between April 2007 and December 2013. Of these, 13 patients with unresectable primary tumors due to multiple organ invasion and 22 patients with resectable or possibly resectable metastases were excluded from the study. Furthermore, 6 patients who were indicated for supportive care, and 5 patients with malignancies other than colorectal adenocarcinoma, including neuroendocrine carcinoma, appendiceal cystadenocarcinoma, squamous cell carcinoma of the anal canal, and multiple cancers under treatment, were also excluded, resulting in 57 patients with a resectable primary tumor but unresectable metastases being included in this study (Figure [1](#Fig1){ref-type="fig"}). Decision making of each treatment option was owing to the patients' choice under sufficient informed consent from main surgeons and/or medical oncologists. Fifteen patients were treated with up-front systemic chemotherapy (USC) as initial therapy and 42 were treated with primary tumor resection (PTR) followed by chemotherapy.Figure 1Inclusion criteria.

This study was performed with permission of the Ethics Committee of the Hiroshima University.

Chemotherapy {#Sec4}
------------

During the study period, almost all anti-cancer drugs indicated for CRC were available in Japan; 5-fluorouracil/leucovorin, capecitabine, S-1, oxaliplatin, irinotecan, bevacizumab, cetuximab (since August 2008), and panitumumab (since April 2010) were all administered to the patients, while regorafenib or trifluridine were not. As a general rule of our institute, oxaliplatin-based doublet chemotherapy (mFOLFOX6 or XELOX) with any molecular targeted agent was selected as first-line chemotherapy, and subsequently irinotecan-based doublet chemotherapy (FOLFIRI) with any molecular targeted agent was selected as second line, although chemotherapy regimens were finally decided on an individual basis by the attending medical oncologists. Bevacizumab was administered even when a primary tumor was present in the USC group, and administered at least 1 month after primary tumor resection in the PTR group, because of its possible role in delayed wound healing. Genotyping of Kirsten rat sarcoma viral oncogene (*KRAS*) exon 2 was performed for all cases from April 2010, when the Japanese Ministry of Health and Welfare approved its reimbursement for patients with health insurance. Before approval, the *KRAS* exon 2 was genotyped only when cetuximab or panitumumab was considered; therefore, the *KRAS* status was unknown in some cases. Cetuximab and panitumumab were offered only when a wild-type *KRAS* exon 2 genotype was confirmed. Other *RAS* genotypes were not studied.

Statistical analyses {#Sec5}
--------------------

The following baseline characteristics were compared between the USC and PTR groups: age, sex, body mass index (BMI), Eastern Cooperative Oncology Group performance status (ECOG-PS) \[[@CR18]\], American Society of Anesthesiologists score (ASA score), tumor location (colon or rectum), *KRAS* status, carcinoembryonic antigen (CEA), invasion depth and lymph node metastases classified according to the UICC-TNM stage (Union for International Cancer Control 7th edition \[[@CR19]\]), sum of the longest diameters of the three largest metastases, number of metastases, number of organs with metastasis, and chemotherapy regimens (number of courses and anti-cancer drugs used). The operative procedures were also analyzed in both PTR and USC groups. Moreover, postoperative morbidity, response rate, disease control rate in both groups, and symptom occurrence rate after initiation of USC by primary tumor progression were studied. The results are reported as median and interquartile range for quantitative variables and as frequencies for categorical variables. Comparisons were conducted using Wilcoxon's rank-sum tests for quantitative variables and Fisher's exact tests or Pearson's Chi-square tests for categorical variables.

Survival outcomes were analyzed as of September 2014 and were compared between the two groups using log-rank tests and summarized as Kaplan-Meier curves and hazards ratios (HRs) with 95% confidence intervals (CIs). Subsequently, multivariate analyses for survival were conducted using Cox proportional hazard models, including variables at *P* \< 0.1 in the log-rank tests. The results of these univariate or multivariate analyses are presented as the odds ratio (OR) or HR and 95% CI with the corresponding *P* value.

All statistical analyses were performed using JMP 10 software (SAS Institute, Cary, NC, USA).

Results {#Sec6}
=======

On analyses of the baseline demographic and clinicopathological characteristics, sex and the primary tumor sites were found to significantly differ between the two groups, whereas other variables such as the age, BMI, ECOG-PS, ASA score, CEA, *KRAS* status, depth of invasion, lymph node metastasis, sum of the longest tumor diameter, number of metastases, number of organs with metastasis, peritoneal dissemination, and chemotherapy regimens did not significantly differ (Table [1](#Tab1){ref-type="table"}). There were no differences with regard to the operative procedure offered to patients in both groups (Table [2](#Tab2){ref-type="table"}). The median survival times were 13.4 months and 23.9 months for the USC and PTR groups, respectively, as determined by using the Kaplan-Meier analyses, and there was no statistical significance in overall survival (OS) (Figure [2](#Fig2){ref-type="fig"}). Moreover, the multivariate Cox regression analysis did not reveal any significant differences in survival between the two treatment options, whereas the *KRAS* status and number of organs with metastasis was found to be a significant independent prognostic factor for the survival of patients with CRC in the current study (Table [3](#Tab3){ref-type="table"}).Table 1**Baseline demographic and clinicopathological characteristicsCharacteristicUSC (** ***N***  **= 15)PTR (** ***N***  **= 42)*P*** **value**Follow-up duration (months)13.4 (11.3 to 23.2)19.2 (12.4 to 28.9)0.232Age (years)63 (48 to 65)61.5 (54 to 70.5)0.568SexMale780.048Female834BMI (kg/m^2^)21.2 (16.9 to 25.5)21.4 (19.8 to 23.1)0.978Performance status014391.00113≥200ASA score13100.94921129313400Primary tumor siteRight colon1130.005Left colon318Rectum1111KRAS statusWild type6240.368Mutant or unknown918CEA23.1 (4.1 to 60.3)41.5 (12.9 to 344)0.074Invasion depthT2010.337T3617T4a920T4b04Lymph node metastasisNegative151.00Positive1437Sum of the longest diameters of metastases (mm)61 (46 to 150)75 (41.5 to 109)0.697Number of metastases17 (6 to 52)11.5 (5.5 to 28)0.309Number of organs with metastasis2 (1 to 2)2 (1 to 2)0.899Peritoneal dissemination2 (13.3%)7 (16.7%)1.00Total lines of chemotherapy2 (2 to 3)2 (1 to 3)1.00Use or any molecular target agents13 (86.7%)37 (88.1%)1.00Bevacizumab12 (80.0%)33 (78.6%)1.00Cetuximab and/or panitumumab\*6 (100%)16 (66.7%)0.155Use of oxaliplatine combination14 (93.3%)36 (85.7%)0.66Use irinotecan combination12 (80.0%)26 (61.9%)0.339Conversion1 (6.7%)0 (0%)0.263USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. BMI: body mass index. ASA score: American Society of Anesthesiologists score. KRAS: Kirsten rat sarcoma viral oncogene. CEA: carcinoembryonic antigen. Variables were statistically analyzed by Wilcoxon's rank-sum test (quantitative variables), Fisher's exact test (categorical, binary) or Chi-square test (categorical, more than three variables). \*Use of cetuximab and/or panitumumab was presented as frequency in the KRAS exon 2 wild-type tumor only.Table 2**Surgical procedures offered to patients in the PTR and USC groupsPTR (** ***N***  **= 42)USC (** ***N***  **= 6)*P*** **value**Surgical procedure, *n* Ileocecal resection5-0.181 Right hemicolectomy4- Transverse colectomy4- Left hemicolectomy2- Sigmoidectomy112 Hartmann operation31 Abdominoperineal resection5- High anterior resection3- Low anterior resection52 Only ostomy creation-1Approach0.591 Open344 Laparoscopic82Open conversion, *n*00N.A.USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. N.A.: not available. Variables were statistically analyzed by Fisher's exact test (categorical, binary) or Chi-square test (categorical, more than three variables).Figure 2Overall survival between the USC and PTR groups. Median survival times were 13.4 and 23.9 months in USC and PTR, respectively, and overall survival was not significantly different in the two groups. USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. HR: hazard ratio. CI: confidence interval.Table 3**Univariate and multivariate analysis on overall survivalUnivariate analysisMultivariate analysisFactor*N*HR (95% CI)*P*** **valueHR (95% CI)*P*** **value**Treatment PTR42Reference0.093Reference0.495 USC151.76 (0.87 to 3.35)1.30 (0.60 to 2.73)Age \<63 years30Reference0.923\-- ≥63 years270.97 (0.52 to 1.80)Sex Male15Reference0.116\-- Female421.70 (0.84 to 3.24)BMI \<22 kg/m^2^33Reference0.627\-- ≥22 kg/m^2^240.85 (0.44 to 1.61)Tumor location Colon35Reference0.280\-- Rectum220.70 (0.35 to 1.32)KRAS status Wild type30Reference0.001Reference0.004 Mutant or unknown272.81 (1.49 to 5.31)2.89 (1.41 to 6.02)CEA \<5.110Reference0.822\-- ≥5.1471.09 (0.53 to 2.56)Invasion depth T1-324Reference0.0540Reference0.065 T4a, T4b331.93 (0.99 to 3.87)1.97 (0.96 to 4.24)Lymph node metastasis Negative6Reference0.225\-- Positive512.47 (0.89 to 10.2)Sum of the longest diameters of metastases \<67 mm29Reference0.184\-- ≥67 mm281.52 (0.82 to 2.87)Number of metastases \<1329Reference0.084Reference0.199 ≥13281.72 (0.93 to 3.24)1.55 (0.79 to 3.09)Number of organs with metastasis 122Reference0.010Reference0.037 ≥2352.52 (1.26 to 5.48)2.14 (1.04 to 4.76)Peritoneal dissemination No48Reference0.129\-- Yes91.90 (0.76 to 4.16)Total lines of chemotherapy 1 to 235Reference0.111\-- ≥3220.60 (0.31 to 1.13)Use of anti-VEGF antibody No12Reference0.403\-- Yes450.71 (0.34 to 1.69)Use of anti-EGFR antibody (KRAS wild patient only) No8Reference0.197\-- Yes222.22 (0.73 to 9.59)USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. HR: hazard ratio. CI: confidence interval. BMI: body mass index. KRAS: Kirsten rat sarcoma viral oncogene. EGFR: epidermal growth factor receptor. CEA: carcinoembryonic antigen. VEGF: vascular endothelial growth factor.

The response rates to first-line chemotherapy were 33.3% and 42.9% in the USC and PTR groups, respectively (*P* = 0.558), while the disease control rates were 80.0% and 71.4%, respectively (*P* = 0.735). In the USC group, 3 patients (20.0%) experienced symptoms due to primary tumor after initiation of chemotherapy, resulting in additional surgery. For one of the three, emergency laparotomy was required because of perforative peritonitis caused by tumor necrosis after USC. On the other hand, 3 patients received primary tumor resection, not as palliation for symptoms caused by the primary tumors but as a multidisciplinary therapy after the primary tumors and metastases were controlled with up-front chemotherapy. In total, 6 patients received the surgery, and 3 patients (50%) experienced postoperative morbidity, including 2 surgical site infections (SSI), 1 anastomotic leakage, and 1 pneumonia.

In the PTR group, the morbidity was observed in 18 cases (42.9%), including 6 postoperative ileuses, 3 anastomotic leakages, 3 surgical site infections, and 10 cases with other complications such as liver function test abnormalities and delirium. Of these, 6 cases (14.3%) were categorized as \> grade 3 complications.

Discussion {#Sec7}
==========

In stage IV CRC with unresectable metastases, whether primary tumor resection followed by chemotherapy or up-front systemic chemotherapy provides a better prognosis remains controversial. Contrary to our result that the OS rates do not differ according to primary tumor resection in stage IV CRC with unresectable metastases, some previous reports have indicated a better survival benefit with primary tumor resection. In a recent meta-analysis of eight studies with available survival data, primary tumor resection was associated with longer OS, with an estimated median standardized difference of 6.0 months \[[@CR11]\]. In another meta-analysis of 21 studies, primary tumor resection also contributed to longer OS; however, most of the studies included were retrospective (18 of 21) and chemotherapy regimens differed from each other. With regard to molecular targeted agents, only two study included bevacizumab and one cetuximab (with bevacizumab) \[[@CR20]\]. Additionally, two recent sub-analyses of data from randomized trials \[[@CR12],[@CR13]\] showed the survival benefits for patients who underwent primary tumor resection. Although these were discrepant to our result, it may be because stage IV disease included many complicated conditions, such as the resectability of primary tumor, the volume of metastatic tumor, the pace of progression, and so on. To minimize the influence of these complicated situations, only patients with stage IV disease with a resectable primary tumor but unresectable metastases were included in the current study. For the same purpose, we evaluated the sum of the longest diameters of the metastases, number of metastases, and number of organs with metastasis and confirmed that there were no statistical differences between the two groups.

Moreover, the rapid progress made in the therapeutic treatments for colorectal cancer should also be considered. For example, anti-epidermal growth factor receptor (*EGFR*) antibodies were not included or mentioned in most of these previous studies. While only one study has mentioned the use of cetuximab \[[@CR13],[@CR20],[@CR21]\], which was added to combination therapy regimens comprising capecitabine, oxaliplatin, and bevacizumab, this regimen was not used as standard therapy, because no survival prolongation from adding cetuximab on bevacizumab has been demonstrated. It is notable that an anti-*EGFR* antibody was used in 73.3% of all patients who had *KRAS* wild-type tumors in the current study. Moreover, we did not observe any significant differences in the rates in which both cytotoxic and molecular targeted agents including anti-*EGFR* antibodies were used between the USC and PTR groups. Consequently, the influences by the varied chemotherapy regimens on the result might be minimal.

In addition to primary tumor resection, the *KRAS* mutation was found to have a negative prognostic value in our multivariate analysis, while a prognostic value of *KRAS* mutation on survival in metastatic CRC is controversial in the previous literatures \[[@CR22]\]. *KRAS* mutation was not found to affect the survival in some studies \[[@CR23]-[@CR26]\]. However, most recently, worse OS rates were reported in patients with mutated *KRAS* compared to patients with wild-type *KRAS* in a sub-analysis of a previous randomized controlled study (RCT) with a large sample size \[[@CR27]\]. The result of the current study is compatible with the most recent literature.

Because the OS rates did not significantly differ between the PTR and USC groups in the present study, it is important to evaluate the characteristics of these treatments to determine which leads to a better outcome. USC offers the possibility of avoiding potentially unnecessary primary tumor resection, and accordingly, the primary tumors were controlled in 80.0% of patients in the USC group in this study. However, it should be noted that emergency laparotomy in the USC group owing to perforation was performed in one case (6.7%). On the other hand, 42.9% of patients in the PTR group experienced morbidities, which is higher than the morbidity rates observed in patients undergoing elective surgery for stages 0 to III CRC at our hospital (28.7% in control group, Table [4](#Tab4){ref-type="table"}). The high morbidity rate reported in the present study should raise some concerns. There were no statistical differences in each complication, such as postoperative ileus, anastomotic leakage, and SSI, but the number in every complication is larger in the PTR group. As the sum, morbidity is thought to be more frequent in the PTR group in the current study. In some previous reports \[[@CR6]-[@CR9]\], postoperative morbidity and mortality in PTR are reported to be higher than non-resection group such as ostomy and bypass. However, the reason for higher morbidity and mortality is still unclear. Further studies aiming to compare directly stage IV CRC to stages 0 to III should be required to estimate this issue in the future.Table 4**Complication in PTR compared with elective surgery for stages 0 to III in our hospitalPTR (** ***N***  **= 42)Control (** ***N***  **= 352)*P*** **value**Mortality0%0%N.A.MorbidityOverall18 (42.9%)98 (28.7%)0.0498\>Grade 36 (14.3%)38 (10.7%)0.445Postoperative ileus6 (14.3%)29 (8.2%)0.244Leakage3 (7.1%)20 (5.7%)0.731Surgical site infection5 (11.9%)32 (9.1%)0.574PTR: primary tumor resection group. Control: groups in which elective surgery for stages 0 to III CRC were performed between 2010 and 2012 in our hospital. N.A.: not available. Variables were statistically analyzed by Fisher's exact test.

The limitation of the current study was its retrospective nature. The small number of patients, especially in the USC group, is also the limitation in our study. This is because the concept of USC is thought to emerge after the appearance of molecular targeted agents that potentially enable conversion therapies, and therefore, we have not experienced the large number of patients yet. Although our result may not be conclusive, it suggests that it is important to consider the benefits and disadvantages of both these treatments and to select an appropriate option on an individual basis until standard therapy might be determined in the future based on the results of ongoing RCTs.

Conclusions {#Sec8}
===========

Our results here indicate that the OS did not differ significantly depending on the performance of primary tumor resection in stage IV CRC with unresectable metastases. Furthermore, up-front systemic chemotherapy may be valuable in avoiding unnecessary primary tumor resection and surgical morbidity.
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